ICU Medical (NASDAQ:ICUI) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of ICU Medical (NASDAQ:ICUI) from a hold rating to a buy rating in a research report sent to investors on Monday.

Other analysts also recently issued reports about the company. Piper Sandler raised their price objective on ICU Medical from $153.00 to $172.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. KeyCorp lifted their price target on shares of ICU Medical from $173.00 to $175.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of ICU Medical in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $175.67.

ICU Medical Stock Up 1.2%

Shares of NASDAQ ICUI opened at $155.13 on Monday. The company has a market capitalization of $3.83 billion, a P/E ratio of -500.40 and a beta of 0.80. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.45 and a quick ratio of 1.19. The company has a 50 day simple moving average of $146.22 and a 200-day simple moving average of $132.55. ICU Medical has a 1 year low of $107.00 and a 1 year high of $175.51.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $2.03 EPS for the quarter, beating analysts’ consensus estimates of $1.43 by $0.60. The firm had revenue of $533.30 million for the quarter, compared to analysts’ expectations of $511.46 million. ICU Medical had a positive return on equity of 7.71% and a negative net margin of 0.32%.The firm’s quarterly revenue was down 8.9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.59 earnings per share. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. On average, equities research analysts predict that ICU Medical will post 4.11 earnings per share for the current year.

Insider Transactions at ICU Medical

In other news, Director Elisha W. Finney sold 1,285 shares of the firm’s stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $140.42, for a total value of $180,439.70. Following the completion of the transaction, the director owned 3,995 shares of the company’s stock, valued at approximately $560,977.90. This trade represents a 24.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Virginia Ruth Sanzone sold 930 shares of the stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $142.34, for a total transaction of $132,376.20. Following the sale, the vice president owned 5,456 shares in the company, valued at approximately $776,607.04. This trade represents a 14.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 1.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Millennium Management LLC grew its holdings in shares of ICU Medical by 173.4% during the third quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock worth $130,638,000 after purchasing an additional 690,694 shares during the last quarter. River Road Asset Management LLC boosted its position in shares of ICU Medical by 207.0% in the 2nd quarter. River Road Asset Management LLC now owns 651,492 shares of the medical instruments supplier’s stock valued at $83,658,000 after purchasing an additional 439,263 shares during the period. Norges Bank acquired a new stake in shares of ICU Medical in the 2nd quarter valued at about $36,633,000. UBS Group AG grew its stake in ICU Medical by 239.8% during the 3rd quarter. UBS Group AG now owns 386,555 shares of the medical instruments supplier’s stock worth $46,371,000 after buying an additional 272,782 shares during the last quarter. Finally, William Blair Investment Management LLC acquired a new position in ICU Medical during the second quarter worth approximately $27,928,000. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.